These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 11305804

  • 1. Elevated tissue factor circulating levels in children with hemolytic uremic syndrome caused by verotoxin-producing E. coli.
    Kamitsuji H, Nonami K, Murakami T, Ishikawa N, Nakayama A, Umeki Y.
    Clin Nephrol; 2000 May; 53(5):319-24. PubMed ID: 11305804
    [Abstract] [Full Text] [Related]

  • 2. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI.
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Erythrocyte P1 group antigen expression in VTEC-associated hemolytic uremic syndrome.
    Ashida A, Matsui K, Chizaki T, Yoshikawa K, Kawamura N, Suzuki K, Tamai H.
    Clin Nephrol; 1999 Feb; 51(2):73-6. PubMed ID: 10069641
    [Abstract] [Full Text] [Related]

  • 6. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [Abstract] [Full Text] [Related]

  • 7. Vero cytotoxin binding to polymorphonuclear leukocytes among households with children with hemolytic uremic syndrome.
    te Loo DM, Heuvelink AE, de Boer E, Nauta J, van der Walle J, Schröder C, van Hinsbergh VW, Chart H, van de Kar NC, van den Heuvel LP.
    J Infect Dis; 2001 Aug 15; 184(4):446-50. PubMed ID: 11471102
    [Abstract] [Full Text] [Related]

  • 8. Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome.
    Proulx F, Toledano B, Phan V, Clermont MJ, Mariscalco MM, Seidman EG.
    Pediatr Res; 2002 Dec 15; 52(6):928-34. PubMed ID: 12438672
    [Abstract] [Full Text] [Related]

  • 9. Plasma levels of granulocyte elastase-alpha1-proteinase inhibitor complex in children with hemolytic uremic syndrome caused by verotoxin-producing Escherichia coli.
    Ishikawa N, Kamitsuji H, Murakami T, Nakayama A, Umeki Y.
    Pediatr Int; 2000 Dec 15; 42(6):637-41. PubMed ID: 11192520
    [Abstract] [Full Text] [Related]

  • 10. Association between hemolytic uremic syndrome and verotoxin-producing strains of E. coli.
    Jure MA, de Saab OA, de Castillo MC, Sesma F, Miceli S, Zamora AM, de Ruiz Holgado AP, de Nader OM.
    Rev Latinoam Microbiol; 1998 Dec 15; 40(1-2):1-8. PubMed ID: 10932728
    [Abstract] [Full Text] [Related]

  • 11. Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome.
    Chaisri U, Nagata M, Kurazono H, Horie H, Tongtawe P, Hayashi H, Watanabe T, Tapchaisri P, Chongsa-nguan M, Chaicumpa W.
    Microb Pathog; 2001 Aug 15; 31(2):59-67. PubMed ID: 11453701
    [Abstract] [Full Text] [Related]

  • 12. Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human sera.
    Watarai S, Yokota K, Tana, Kishimoto T, Kanadani T, Taketa K, Oguma K.
    J Clin Microbiol; 2001 Feb 15; 39(2):798-800. PubMed ID: 11158156
    [Abstract] [Full Text] [Related]

  • 13. Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome.
    Arbus GS.
    Kidney Int Suppl; 1997 Mar 15; 58():S91-6. PubMed ID: 9067954
    [Abstract] [Full Text] [Related]

  • 14. Enterohaemorrhagic Escherichia coli in human medicine.
    Karch H, Tarr PI, Bielaszewska M.
    Int J Med Microbiol; 2005 Oct 15; 295(6-7):405-18. PubMed ID: 16238016
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
    Lizakowski S, Zdrojewski Z, Jagodzinski P, Rutkowski B.
    Scand J Urol Nephrol; 2007 Oct 15; 41(3):237-42. PubMed ID: 17469034
    [Abstract] [Full Text] [Related]

  • 17. [A novel marker of development of HUS associated with enterohemorrhagic Escherichia coli infection--thrombomodulin levels in the blood].
    Nagayama K.
    Nihon Rinsho; 1997 Mar 15; 55(3):747-50. PubMed ID: 9086792
    [Abstract] [Full Text] [Related]

  • 18. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I, Wysokin Ski W, Karnicki K, Adamiec R.
    Int Angiol; 2008 Aug 15; 27(4):296-301. PubMed ID: 18677291
    [Abstract] [Full Text] [Related]

  • 19. [Evaluation of thrombomodulin and tumor necrosis factor-alpha levels in patients with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection].
    Yamamoto T, Isokawa S, Miyata H, Yoshioka K.
    Nihon Jinzo Gakkai Shi; 1999 Apr 15; 41(2):60-4. PubMed ID: 10361420
    [Abstract] [Full Text] [Related]

  • 20. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.
    Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB.
    J Infect Dis; 2002 Aug 15; 186(4):493-500. PubMed ID: 12195376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.